for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Champions Oncology Inc

CSBR.OQ

Latest Trade

9.24USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4.02

 - 

10.81

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.24
Open
--
Volume
--
3M AVG Volume
0.57
Today's High
--
Today's Low
--
52 Week High
10.81
52 Week Low
4.02
Shares Out (MIL)
12.73
Market Cap (MIL)
117.61
Forward P/E
--
Dividend (Yield %)
--

Next Event

Champions Oncology Inc Annual Shareholders Meeting

Latest Developments

More

Champions Biotechnology Reports Rise Of 14% In Qtrly Rev

Champions Biotechnology Q2 Revenue Up 28.6 Pct

Champions Oncology Reports Q1 Revenue Rose 23.7 Pct To $6.2 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Champions Oncology Inc

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.

Industry

Biotechnology & Drugs

Contact Info

855 N Wolfe St Ste 619

BALTIMORE, MD

21205-1511

United States

+1.410.3690365

https://championsoncology.com

Executive Leadership

Joel Ackerman

Chairman of the Board

Ronnie Morris

Chief Executive Officer, Director

David Miller

Chief Financial Officer

David Sidransky

Lead Independent Director

Philip Breitfeld

Independent Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

0.070

2020

-0.140

2021(E)

0.067
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.37
Price To Book (MRQ)
21.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.31
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-14.66
Return on Equity (TTM)
-6.95

Latest News

Latest News

BRIEF-Champions Oncology Reports Quarterly Revenue Of $9.0 Mln, An Increase Of 40% Year-Over-Year

* CHAMPIONS ONCOLOGY INC -QUARTERLY REVENUE OF $9.0 MILLION, AN INCREASE OF 40% YEAR-OVER-YEAR

BRIEF-Champions Oncology Reports Quarterly Revenue Of $5.1 Million

* CHAMPIONS ONCOLOGY REPORTS QUARTERLY REVENUE OF $5.1 MILLION

BRIEF-Champions Oncology Reports Record Quarterly Revenue Of $5.2 Million

* CHAMPIONS ONCOLOGY REPORTS RECORD QUARTERLY REVENUE OF $5.2 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up